Riba will cause anemia on it's own.
The primary toxicity of Ribavirin is hemolytic anemia, which was observed in approximately 13% of all Ribavirin/peginterferon alfa-2a- treated subjects in clinical trials. Anemia associated with Ribavirin occurs within 1 to 2 weeks of initiation of therapy. Because the initial drop in hemoglobin may be significant, it is advised that hemoglobin or hematocrit be obtained pretreatment and at week 2 and week 4 of therapy or more frequently if clinically indicated. Patients should then be followed as clinically appropriate. Caution should be exercised in initiating treatment in any patient with baseline risk of severe anemia (e.g., spherocytosis, history of gastrointestinal bleeding)
According to the prescribing info document for Sovaldi the incidence of anemia in all trial groups receiving Soavldi/Ribavirin therapy was 6%-10%
Take a look at page 6 here:
Thanks for your responses. Both were helpful
I continued reading Page 7 of the prescribing info for Sovaldi and if I am interpreting the info correctly, Ribavirin in combination with interferon has a much higher incidence of anemia.
As I mentioned in my original post my husband had to stop triple treatment after 5 weeks because of severe anemia. It was really awful so no wonder I am apprehensive about the Ribavirin piece of this new treatment. But I think these statistics make me feel better since interferon is not part of this treatment. I think his doctor is on top of it because she plans to start him on a lower dosage of Ribavirin and increase it in increments.
He has been through hell these three years and I am praying that he will see SVR with this treatment and be able to address his other complications without Hep C taunting him/us any more.
Your prayers and good thoughts on his behalf (and everyone in similar circumstance) for a successful treatment will mean so much everyone.
Hi Nan, This subject is of interest to me as well since I am now on day 4 of Sovaldi/Ribavirin therapy. Keep in mind the statistics cited in the prescribing info is from trials. There is a relatively small amount of data used to compile these results, just a few hundred patients total. Some patients groups are quite small. There are multiple variables, such as co-morbidities, etc that may not have been represented in the trial group. Many trials explicitly exclude certain conditions. Since we are now in the "real world" of this therapy being prescribed more information will become available as time passes. I have been asked to report any side effects or anything at all that might be relevant to Gilead through supportpath.com so they may expand their database. So far I have nothing to report thankfully. I will await the results of my 2 week blood draw with great interest.....
Anemia observed with SOF+RBV and SOF+PEG/RBV treatment
Hemoglobin reductions with SOF+RBV similar to historical data with RBV monotherapy 1,2
RBV monotherapy results in ~2 g/dL reduction
Interferon contributes to anemia through bone marrow suppression
PEG/RBV results in ~3.5 g/dL reduction
Having gone through the triple treatment (with Incivik) experience, I know exactly what you mean. The thinking was that that would be the end of the virus also. How disappointing it was when he had to stop treatment. The real world results are what counts.
Please let us know how your treatment progresses (any signs of anemia, side effects, etc.) I am praying that you will soon see/hear the word "undetected".